Introduction The escalating threat of multidrug-resistant organisms necessitates constant exploration for novel antimicrobial agents. Eravacycline, a next-generation tetracycline derivative, has emerged as a promising solution due to its unique chemical structure, which enhances potency and expands its spectrum of activity.